{"id":"tp-56026","type":"article-newspaper","title":"Spero Therapeutics Posts $0.76 Q3 Loss Per Share, Cash Runway Into 2029","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/56026","datePublished":"2026-11-12T23:15:34.000Z","dateModified":"2026-11-12T23:15:34.000Z","language":"en","abstract":"The company had $107.9 million in cash and equivalents on Sept. 30, 2026, and expects the funds to support operations into the second half of 2029.","section":"Business","references":[]}